Look for:

Our offer for

VERTEX PHARMACEUTICALS INC.


ISIN:
US92532F1003
WKN:
92532F100

2023/02/07 22:00:00
Price
308.54 USD
Difference 1.20% (3.67)

General attributes

ISINUS92532F1003
SymbolVRTX
ExchangeNasdaq
CurrencyUSD
SectorChemical / Pharmaceutical / Health
Security typeStock
Market cap (m)73,818 EUR
BenchmarkS&P 500

Market data

Bid (Bid size)307.00 USD (100)
Ask (Ask size)308.54 USD (100)
Open303.59 USD
High309.44 USD
Low302.24 USD
Close (prev. day)304.87 USD
VWAP306.869892 USD
Volume (pcs)1,300,784
Trading volume399,148,462.22
Number of trades25,392
Last size220,389

Futures and Options

Related Futures-
Related Options-

PDF Downloads

Company report: VERTEX PHARMACEUTICALS INC.PDF Download

Scale: ABS REL         Instrument

Add Benchmark:



Information about previous performance does not guarantee future performance.
Source: FactSet

Recent research



2023/02/07 22:00:00
Price
308.54 USD
Difference 1.20% (3.67)

General attributes

ISINUS92532F1003
SymbolVRTX
ExchangeNasdaq
CurrencyUSD
SectorChemical / Pharmaceutical / Health
Security typeStock
Market cap (m)73,818 EUR
BenchmarkS&P 500

Market data

Bid (Bid size)307.00 USD (100)
Ask (Ask size)308.54 USD (100)
Open303.59 USD
High309.44 USD
Low302.24 USD
Close (prev. day)304.87 USD
VWAP306.869892 USD
Volume (pcs)1,300,784
Trading volume399,148,462.22
Number of trades25,392
Last size220,389

Performance and Risk

6m1Y3Y
Perf (%)+1.75%+35.38%+31.36%
Perf (abs.)+4.95+75.25+68.75
Beta0.530.600.72
Volatility30.8231.5537.25
Scale: ABS REL         Instrument

Add Benchmark:



Information about previous performance does not guarantee future performance.
Source: FactSet

Price data

Ø price 5 days | Ø volume 5 days (pcs.)307.10 USD (1,477,367)
Ø price 30 days | Ø volume 30 days (pcs.)301.81 USD (1,357,710)
Ø price 100 days | Ø volume 100 days (pcs.)302.50 USD (1,451,214)
Ø price 250 days | Ø volume 250 days (pcs.)282.02 USD (1,518,822)
YTD High | date325.19 USD (2023/01/31)
YTD Low | date282.21 USD (2023/01/09)
52 Weeks High | date325.19 USD (2023/01/31)
52 Weeks Low | date225.28 USD (2022/02/24)

All listings for VERTEX PHARMACEUTICALS INC.

Exchange  DateTimePriceTrading volume (mio.)Number of trades
BX Swiss2023/01/2618:00289.224 CHF0.001
Berlin2023/02/0708:08283.20 EUR0.001
Duesseldorf2023/02/0721:00285.55 EUR0.0011
Frankfurt2023/02/0708:05283.25 EUR0.001
Hamburg2023/02/0708:01283.20 EUR0.001
Hanover2023/02/0708:02283.20 EUR0.001
London Stock Exchange2023/01/2315:30309.59 USD0.001
Munich2023/02/0708:00283.10 EUR0.001
Nasdaq2023/02/0722:00308.54 USD399.1525,392
Stuttgart2023/02/0708:01283.20 EUR0.003
Tradegate2023/02/0722:26287.80 EUR0.0212
Vienna Stock Exchange2023/02/0717:32285.00 EUR0.002
Xetra2023/02/0717:35285.00 EUR0.026

Company Logo

https://gateway.mdgms.com/extern/logo_image.html?ID_LOGO=15368&ID_TYPE_IMAGE_LOGO=2

Contact Details

VERTEX PHARMACEUTICALS INC.
- -
50 Northern Avenue - 02210 Boston
Telefon: 1-617-341-6100
Fax: -
E-mail: mediainfo@vrtx.com

PDF Downloads

Company report: VERTEX PHARMACEUTICALS INC.PDF Download

Company Profile

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Members of Management Board

Jeffrey LeidenChairman of Board of Directors
Alan GarberMember of Board of Directors
Sangeeta BhatiaMember of Board of Directors
Bruce SachsMember of Board of Directors
Diana McKenzieMember of Board of Directors
Lloyd CarneyMember of Board of Directors
Margaret McGlynnMember of Board of Directors
Suketu UpadhyayMember of Board of Directors
Terrence KearneyMember of Board of Directors
Yuchun LeeMember of Board of Directors
Reshma Kewalramani, M.D.Chairman of Managing Board
David AltshulerMember of Executive Committee
Jeffrey LeidenMember of Executive Committee
Amit K. SachdevMember of Executive Committee
Bastiano Sanna, Ph.D.Member of Executive Committee
Carmen Bozic, M.D.Member of Executive Committee
Charles F. Wagner, Jr.Member of Executive Committee
Damian WimotMember of Executive Committee
Joy LiuMember of Executive Committee
Ludovic FenauxMember of Executive Committee
Mark BunnageMember of Executive Committee
Michael PartridgeMember of Executive Committee
Mike TirozziMember of Executive Committee
Nia Tatsis, Ph.D.Member of Executive Committee
Nina DevlinMember of Executive Committee






Decline
Accept

We use cookies and web analysis software to give you the best possible experience on our website. If you consent, these tools will be used. Please read more information here

INFORMATION FOR PRIVATE CLIENTS / CONSUMERS

Any information, material and services regarding financial instruments and securities provided by Česká spořitelna/Erste Group/ or any of its affiliates (collectively “Erste Group“) on this and any linked website hereafter (jointly the “Websites“) shall be exclusively to investors who are not subject to any legal sale or purchase restrictions.

By agreeing to this hereto, the visitor entering this Websites confirms that has read, understood and accepted this Information and the Disclaimer